ARTV Stock Overview
A clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Artiva Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.00 |
| 52 Week High | US$16.00 |
| 52 Week Low | US$11.12 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
Shareholder Returns
| ARTV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.0% | 3.1% | -1.4% |
| 1Y | n/a | 16.3% | 16.9% |
Return vs Industry: Insufficient data to determine how ARTV performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ARTV performed against the US Market.
Price Volatility
| ARTV volatility | |
|---|---|
| ARTV Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ARTV has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ARTV's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 81 | Fred Aslan | www.artivabio.com |
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate.
Artiva Biotherapeutics, Inc. Fundamentals Summary
| ARTV fundamental statistics | |
|---|---|
| Market cap | US$279.38m |
| Earnings (TTM) | -US$25.97m |
| Revenue (TTM) | US$32.75m |
8.5x
P/S Ratio-10.8x
P/E RatioIs ARTV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARTV income statement (TTM) | |
|---|---|
| Revenue | US$32.75m |
| Cost of Revenue | US$0 |
| Gross Profit | US$32.75m |
| Other Expenses | US$58.72m |
| Earnings | -US$25.97m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.12 |
| Gross Margin | 100.00% |
| Net Profit Margin | -79.28% |
| Debt/Equity Ratio | 0% |
How did ARTV perform over the long term?
See historical performance and comparison